CSTL CASTLE BIOSCIENCES INC

Nasdaq castlebiosciences.com


$ 34.75 $ 1.70 (5.15 %)    

Monday, 10-Nov-2025 16:23:04 EST
QQQ $ 621.10 $ 0.00 (0 %)
DIA $ 473.81 $ 0.00 (0 %)
SPY $ 680.10 $ 0.00 (0 %)
TLT $ 89.30 $ 0.00 (0 %)
GLD $ 380.82 $ 0.00 (0 %)
$ 34.74
$ 33.11
$ 30.50 x 30
$ 35.00 x 1
-- - --
$ 14.59 - $ 34.83
390,565
na
1.01B
$ 1.63
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-03-2025 09-30-2025 10-Q
2 08-04-2025 06-30-2025 10-Q
3 05-05-2025 03-31-2025 10-Q
4 02-27-2025 01-01-1970 10-K
5 11-04-2024 09-30-2024 10-Q
6 08-05-2024 06-30-2024 10-Q
7 05-02-2024 03-31-2024 10-Q
8 02-28-2024 12-31-2023 10-K
9 11-02-2023 09-30-2023 10-Q
10 08-02-2023 06-30-2023 10-Q
11 05-03-2023 03-31-2023 10-Q
12 02-28-2023 12-31-2022 10-K
13 11-02-2022 09-30-2022 10-Q
14 08-08-2022 06-30-2022 10-Q
15 05-09-2022 03-31-2022 10-Q
16 02-28-2022 12-31-2021 10-K
17 11-08-2021 09-30-2021 10-Q
18 08-09-2021 06-30-2021 10-Q
19 05-10-2021 03-31-2021 10-Q
20 03-11-2021 12-31-2020 10-K
21 11-09-2020 09-30-2020 10-Q
22 08-10-2020 06-30-2020 10-Q
23 05-11-2020 03-31-2020 10-Q
24 03-10-2020 12-31-2019 10-K
25 11-12-2019 09-30-2019 10-Q
26 09-03-2019 06-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-castle-biosciences-rally-might-just-be-getting-started

Castle Biosciences' bullish structure is strengthening as momentum builds ahead of a possible breakout.

 btig-maintains-buy-on-castle-biosciences-raises-price-target-to-38

BTIG analyst Mark Massaro maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and raises the price target from $32 to $38.

 baird-maintains-outperform-on-castle-biosciences-raises-price-target-to-41

Baird analyst Catherine Ramsey maintains Castle Biosciences (NASDAQ:CSTL) with a Outperform and raises the price target from...

 castle-biosciences-rolls-out-advancead-tx-gene-expression-profile-test-to-guide-treatment-for-moderate-to-severe-atopic-dermatitis

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today ann...

 castle-biosciences-raises-fy2025-sales-guidance-from-310000m-320000m-to-327000m-335000m-vs-317599m-est

Castle Biosciences (NASDAQ:CSTL) raises FY2025 sales outlook from $310.000 million-$320.000 million to $327.000 million-$335.00...

 castle-biosciences-q3-adj-eps-002-beats-052-estimate-sales-83043m-beat-71209m-estimate

Castle Biosciences (NASDAQ:CSTL) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(...

 decisiondx-melanoma-validated-across-cutaneous-melanoma-subtypes-in-13560-patients-with-results-to-be-presented-by-castle-biosciences-at-dermatology-conference

This new histological subtype data confirms DecisionDx-Melanoma's clinical value across the spectrum of melanomaCastle Bios...

 castle-biosciences-study-finds-15-of-barretts-esophagus-patients-face-higher-cancer-risk-than-pathology-suggests

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today anno...

 castle-biosciences-expands-decisiondx-scc-test-to-predict-local-recurrence-in-high-risk-skin-cancer-patients

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today anno...

 castle-biosciences-raises-fy2025-sales-guidance-from-28700m-29700m-to-31000m-32000m-vs-29410m-est

Castle Biosciences (NASDAQ:CSTL) raises FY2025 sales outlook from $287.00 million-$297.00 million to $310.00 million-$320.00 mi...

 castle-biosciences-q2-adj-eps-015-beats-049-estimate-sales-8619m-beat-7153m-estimate

Castle Biosciences (NASDAQ:CSTL) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $(...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION